乙琥胺

Ethosuximide
臨床資料
商品名（英語：Drug nomenclature）	Zarontin, others
AHFS/Drugs.com	Monograph
MedlinePlus	a682327
核准狀況	美 DailyMed: Ethosuximide;
懷孕分級	澳: D ; ;
給藥途徑	口服(膠囊劑, 溶液)
ATC碼	N03AD01 (WHO) ;
法律規範狀態
法律規範	歐：Rx-only; 美：處方藥（℞-only）; 處方藥（℞-only）;
藥物動力學數據
生物利用度	93%
藥物代謝	肝臟 (CYP3A4, CYP2E1（英語：CYP2E1）)
生物半衰期	53 小時
排泄途徑	腎 (20%)
識別資訊
	IUPAC命名法 (RS)-3-Ethyl-3-methyl-pyrrolidine-2,5-dione; ;
CAS號	77-67-8
PubChem CID	3291;
IUPHAR/BPS	7182;
DrugBank	DB00593 ;
ChemSpider	3175 ;
UNII	5SEH9X1D1D;
KEGG	D00539 ;
ChEBI	CHEBI:4887 ;
ChEMBL	ChEMBL696 ;
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID7023019 ;
ECHA InfoCard	100.000.954
化學資訊
化學式	C7H11NO2
摩爾質量	141.17 g·mol−1
3D模型（JSmol（英語：JSmol））	交互式圖像;
手性	外消旋體
熔點	64至65 °C（147至149 °F）
	SMILES O=C1NC(=O)CC1(C)CC;
	InChI InChI=1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10) ; Key:HAPOVYFOVVWLRS-UHFFFAOYSA-N ;

乙琥胺是治療失神性癲癇（英語：Absence seizure）的口服藥物^[4]。可以單獨使用，也可以與其他抗癲癇藥品（英語：Anticonvulsant）（如：丙戊酸）併用^[4]。

副作用一般很小^[5]。常見的副作用包括食欲不振、腹痛、腹瀉和疲倦^[4]。嚴重的副作用包括自殺想法（英語：Suicidal ideation）、血球減少（英語：Cytopenia）和紅斑狼瘡^[4] ^[5]。目前寫的懷孕期或 3 歲以下的安全仍不清楚^[4]。乙琥胺屬於丁二酰亞胺類藥物。確定的作用機轉並不清楚^[4]。

乙琥胺於 1960 年在美國取得醫療許可^[4]。名列世界衛生組織基本藥物標準清單^[6]。已有學名藥流通於市^[4]。截至 2004 年，世界上大多數地區都已普遍可得^[7]。但至 2019 年，由於美國的統一定價（英語：Price fixing）或價格操縱的問題，這個藥物在許多國家的取得都受到限制^[8] ^[9] ^[10]。

參見

參考文獻

^ List of nationally authorised medicinal products (PDF). European Medicines Agency.
^ Patsalos PN. Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies. Epilepsia. November 2005,. 46 Suppl 9 (s9): 140–8. PMID 16302888. S2CID 19462889. doi:10.1111/j.1528-1167.2005.00326.x .
^ Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control]. Diário Oficial da União（英語：Diário Oficial da União）. 2023-03-31 (2023-04-04) [2023-08-16]. （原始內容存檔於2023-08-03）（巴西葡萄牙語）.
^ ^4.0 ^4.1 ^4.2 ^4.3 ^4.4 ^4.5 ^4.6 ^4.7 Ethosuximide. The American Society of Health-System Pharmacists. [8 December 2016]. （原始內容存檔於21 December 2016）.
^ ^5.0 ^5.1 World Health Organization. WHO Model Formulary 2008. World Health Organization. 2009: 69, 74–75. ISBN 9789241547659.
^ World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
^ Shorvon, Simon; Perucca, Emilio; Fish, David; Dodson, W. E. The Treatment of Epilepsy. John Wiley & Sons. 2004: 147 [2020-03-30]. ISBN 978-0-470-75245-6. （原始內容存檔於2021-08-28）（英語）.
^ Hempel, Georg. Methods of Therapeutic Drug Monitoring Including Pharmacogenetics. Elsevier. 2019: 241 [2020-04-05]. ISBN 978-0-444-64067-3. （原始內容存檔於2021-08-28）（英語）.
^ Attorney General Tong leads 44-state coalition in antitrust lawsuit against Teva Pharmaceuticals, 19 other generic drug manufacturers, 15 individuals in conspiracy to fix prices and allocate markets for more than 100 different generic drugs (新聞稿). Office of the Attorney General of the State of Connecticut. 12 May 2019 [5 April 2020]. （原始內容存檔於20 April 2020）.
^ States sue generic drug makers, claiming a conspiracy to fix prices. consumeraffairs.com. 14 May 2019 [5 April 2020]. （原始內容存檔於25 April 2020）（英語）.

[1] List of nationally authorised medicinal products (PDF). European Medicines Agency.

[bioavailability-2] Patsalos PN. Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies. Epilepsia. November 2005,. 46 Suppl 9 (s9): 140–8. PMID 16302888. S2CID 19462889. doi:10.1111/j.1528-1167.2005.00326.x .

[3] Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control]. Diário Oficial da União（英語：Diário Oficial da União）. 2023-03-31 (2023-04-04) [2023-08-16]. （原始內容存檔於2023-08-03）（巴西葡萄牙語）.

[AHFS2016-4] 4.0 ^4.1 ^4.2 ^4.3 ^4.4 ^4.5 ^4.6 ^4.7 Ethosuximide. The American Society of Health-System Pharmacists. [8 December 2016]. （原始內容存檔於21 December 2016）.

[WHO2008-5] 5.0 ^5.1 World Health Organization. WHO Model Formulary 2008. World Health Organization. 2009: 69, 74–75. ISBN 9789241547659.

[WHO21st-6] World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

[Sh2008-7] Shorvon, Simon; Perucca, Emilio; Fish, David; Dodson, W. E. The Treatment of Epilepsy. John Wiley & Sons. 2004: 147 [2020-03-30]. ISBN 978-0-470-75245-6. （原始內容存檔於2021-08-28）（英語）.

[Hem2019-8] Hempel, Georg. Methods of Therapeutic Drug Monitoring Including Pharmacogenetics. Elsevier. 2019: 241 [2020-04-05]. ISBN 978-0-444-64067-3. （原始內容存檔於2021-08-28）（英語）.

[9] Attorney General Tong leads 44-state coalition in antitrust lawsuit against Teva Pharmaceuticals, 19 other generic drug manufacturers, 15 individuals in conspiracy to fix prices and allocate markets for more than 100 different generic drugs (新聞稿). Office of the Attorney General of the State of Connecticut. 12 May 2019 [5 April 2020]. （原始內容存檔於20 April 2020）.

[CA2019-10] States sue generic drug makers, claiming a conspiracy to fix prices. consumeraffairs.com. 14 May 2019 [5 April 2020]. （原始內容存檔於25 April 2020）（英語）.

[1]

[2]

[4]

[5]

[6]

[7]

[8]

[9]

[10]